Clin2
NCT07558863Likely a fitRecruiting

GLP-1 medication's effect on nerve damage in type 2 diabetes

Type 2 DiabetesDiabetes With Diabetic Autonomic Neuropathy (Diagnosis)

Treatments studied

Part of Hormones & metabolism clinical trials.

This study tests whether a GLP-1 medication (a type of diabetes drug) can help protect nerves in the heart from damage caused by diabetes. If you have type 2 diabetes and are overweight, this trial might help researchers understand if this medication improves how your heart's nervous system works.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
60 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You are 18–70 years old
  • You have been diagnosed with type 2 diabetes
  • You are overweight or obese (BMI of 24 or higher)
  • You are not pregnant or breastfeeding
  • You do not have pancreas inflammation (pancreatitis) or recent severe diabetes emergencies
  • You do not have heart rhythm problems, thyroid disease, or serious organ damage

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06461377Recruiting· Phase 4
GLP-1RA for heart nerve damage in type 2 diabetes

This trial tests whether a type of diabetes medicine called GLP-1RA can help prevent or improve nerve damage in the heart caused by diabetes. It is for people with type 2 diabetes who are overweight or obese.

Nanjing, Jiangsu
NCT07073053Not yet recruiting· Phase 4
GLP-1 agonists for heart disease in diabetes

This study is testing whether a class of diabetes medicines called GLP-1 receptor agonists can help people with type 2 diabetes and coronary artery disease. If you have recently had a heart artery-opening procedure and are already taking another diabetes medicine called an SGLT2 inhibitor, this trial may be a good fit for you.

Taipei
NCT06487832Recruiting
Effect of diabetes drug on brain response to insulin

This study tests whether a GLP-1 receptor agonist (a type of diabetes medicine) changes how the brain responds to insulin in people with different body sizes. It may help understand if this drug can improve brain function related to insulin.

Tübingen
NCT06686134Recruiting
GLP-1 drug trial for type 2 diabetes

This trial tests a new GLP-1 receptor agonist to improve blood sugar control in people with type 2 diabetes. It may be an option if you haven't used a similar drug in the last three months and your medical records are complete.

Jinan
NCT05390892Recruiting· Phase 4
Preventing kidney and heart damage in type 2 diabetes

This study tests whether diabetes medicines can help prevent worsening heart and kidney problems in people with type 2 diabetes. You’ll be assigned by chance to one of these medicine types, and your other care will be adjusted for safety.

Huntsville, Alabama
NCT07309094Recruiting
Effects of a diabetes drug on fat tissue in kidney disease

This trial tests whether a GLP-1 receptor agonist (a type of diabetes medication) can improve fat tissue health in people with chronic kidney disease who also have type 2 diabetes, cardiovascular disease, or obesity. It may help protect your kidneys and overall health.

Valencia, Valencia

Hear when a new Type 2 diabetes trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.